The majority of survivors who left hospital following Covid-19 did not fully recover five months after discharge and continued to experience negative impacts on their physical and mental health, according to results from the PHOSP-COVID study.
UCLH and Microsoft have announced a new strategic research and innovation collaboration to develop and apply advances in artificial intelligence (AI) and digital technologies for the future of healthcare delivery in the NHS.
A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai is set to begin in the UK and US.
People with heart failure and atrial fibrillation who are hospitalised with Covid-19 are at greater risk of death, according to a large European study involving UCLH.
The UCLH and UCL team behind a life-saving breathing device for Covid-19 patients have won the 2020 Health Service Journal (HSJ) Award for Acute Innovation of the Year.
Read the BRC's latest research magazine for patients and the public.
Dr Rob Bell talks to us about research which found around half of those hospitalised with Covid-19 and who show raised levels of a protein called troponin have suffered some damage to their heart.
Daily infusions of albumin provide no significant health benefit to patients hospitalised with advanced liver cirrhosis, over and above ‘standard care’, according to a large trial.
The Brain Tumour Unit at the NHNN has become a ‘Tessa Jowell Centre of Excellence’ in recognition of its world class brain tumour service and research activity.
More than 31,000 women will be offered kits to carry out smear tests in the privacy of their own homes as part of a UCL-sponsored trial
UCL researchers have been awarded nearly £10 million to look at ‘long-covid’
Researchers at UCLH, UCL and the Francis Crick Institute have embarked on a new study to understand more about how and why people are vulnerable to infection with SARS-CoV-2.
A study has highlighted which factors put people with rheumatic diseases – such as arthritis and lupus – at higher risk of death from Covid-19.
Researchers have begun a trial looking at whether a drug can slow progression of the devastating neurodegenerative condition Multiple System Atrophy (MSA).
The BRC is part of a new collaboration to accelerate cancer research, translating scientific discoveries into tangible benefits for patients.